GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » EBIT per Share

Skye Bioscience (Skye Bioscience) EBIT per Share : $-4.37 (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience EBIT per Share?

Skye Bioscience's EBIT per Share for the three months ended in Mar. 2024 was $-0.16. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.37.

During the past 3 years, the average EBIT per Share Growth Rate was 34.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 25.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was 10.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Skye Bioscience's EBIT per Share or its related term are showing as below:

SKYE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -558.5   Med: 27.35   Max: 46.6
Current: 34

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Skye Bioscience was 46.60% per year. The lowest was -558.50% per year. And the median was 27.35% per year.

SKYE's 3-Year EBIT Growth Rate is ranked better than
83.91% of 1311 companies
in the Biotechnology industry
Industry Median: 3.7 vs SKYE: 34.00

Skye Bioscience's EBIT for the three months ended in Mar. 2024 was $-4.58 Mil.


Skye Bioscience EBIT per Share Historical Data

The historical data trend for Skye Bioscience's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience EBIT per Share Chart

Skye Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.03 -6.32 -4.77 -8.47 -5.24

Skye Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.37 -0.75 -3.13 -0.32 -0.16

Skye Bioscience EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Skye Bioscience's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-36.735/7.006
=-5.24

Skye Bioscience's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

EBIT per Share(Q: Mar. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-4.581/28.000
=-0.16

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Skye Bioscience  (NAS:SKYE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Skye Bioscience EBIT per Share Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Skye Bioscience (Skye Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.
Executives
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Paul A. Grayson director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
5am Ventures Vii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Ventures Iii, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
5am Ventures Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Deborah H. Charych director 1001 17TH ST, SAN FRANCISCO CA 94107